Did not become law. It stopped in the Senate's Judiciary Committee on April 7, 2022. The 2022 session has ended.
2022 Regular Session
Senate Bill 188
AN ACT REQUIRING BRAND NAME PRESCRIPTION DRUG MANUFACTURERS TO PROVIDE SAMPLES OF BRAND NAME DRUGS TO GENERIC PRESCRIPTION DRUG MANUFACTURERS.
What it does
The synopsis the General Assembly published with the bill.
To promote competition in the prescription drug market by allowing developers of generic drugs and biosimilar products to obtain reference samples.
Sponsors
Who carried the bill in each chamber, and who signed on. Each name leads to the member's page.
In the Senate
Sponsor
2 co-sponsors
In the House of Representatives
1 co-sponsor
Its course
February 24 to April 7, 2022, on one scale. In the top row each mark is a day something happened; taller marks are busier days.
Each committee stop sits inside its chamber.
Every action10 actions on 7 days
In the SenateFeb 24 to Apr 7 · stopped42 days
General Law CommitteeFeb 24 to Mar 1519 days
Judiciary CommitteeApr 7 to Apr 7 · stopped0 days
Text
Each version as the General Assembly printed it.
l9n doesn't hold this bill's text yet.
What happened
In l9n's words, one line for each step. Every action as the General Assembly published it is below.
In the Senate Feb 24 – Apr 7
- Feb 24Introduced and sent to General Law Committee
- Feb 25Heard in General Law Committee
- Mar 15General Law Committee recommended it
- Apr 7Sent to Judiciary Committee
All 10 actions, as published
- Feb 24REF. TO JOINT COMM. ONBoth houses
- Feb 25PUBLIC HEARINGBoth houses
- Mar 15Joint FavorableBoth houses
- Mar 16FILED WITH LCOBoth houses
- Mar 24REFERRED TO OLR, OFABoth houses
- Mar 30RPTD. OUT OF LCOBoth houses
- Mar 30FAV. RPT., TAB. FOR CAL., SEN.Senate
- Mar 30SENATE CALENDAR NUMBERSenate
- Mar 30FILE NO.Both houses
- Apr 7REF. BY SEN. TO COMM. ONSenate